Hematology

Headache Relief Shampoo Voted #1 Best New Product in 2019

headache relief shampoo bottles

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019Comments OffHeadache Drug Trial | Headache Relief | Headache Shampoo | Headache Study | Headache Therapy
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Conditions:   Rheumatoid Arthritis;   Arthritis, Rheumatoid
Interventions:   Biological: GSK3196165;   Drug: Tofacitinib 5 mg;   Drug: Placebo to GSK3196165;   Drug: Placebo to tofacitinib;   Drug: Methotrexate;   Drug: Folic (or folinic) acid
Sponsors:   GlaxoSmithKline;   IQVIA
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 10, 2019Comments OffActive | Arthritis | Efficacy | GSK3196165 | Inadequate | Methotrexate | Moderately | Participants | Placebo | Response | Rheumatoid | Safety | Severely | Tofacitinib | Versus
Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant

Conditions:   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cord Blood Transplant Recipient;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm
Intervention:   Biological: Recombinant Interleukin-7
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 9, 2019Comments OffAfter | Blood | Cord | Human | Interleukin7 | Promote | Recombinant | Recovery | Tcell | Transplant
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

Condition:   Breast Cancer
Intervention:   Drug: Rucaparib
Sponsor:   University of Arizona
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 8, 2019Comments OffAffect | Breast | Expression | Inhibitor | Negative | Opportunity | PARP | PDL1 | Rucaparib | Trial | Triple | Tumors | Window
Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors

Condition:   Prostate Cancer
Intervention:   Behavioral: Guided Lifestyle Program Intervention
Sponsors:   Medical College of Wisconsin;   Loyola University Chicago;   Marquette University;   University of Illinois at Chicago
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 7, 2019Comments OffAfricanAmerican | Cancer | Forward | Lifestyle | Moving | Program | Prostate | Survivors
Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer

Condition:   Prostate Cancer
Intervention:   Drug: 18F-DCFPyL
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 6, 2019Comments OffAntigen | Cancer | High | Imaging | Membrane | Prostate | PSMAbased | Risk | Specific
Mechanism of Action Underlying Ketamine s Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Conditions:   Depression;   Major Depressive Disorder;   Major Depression
Interventions:   Drug: Ketamine;   Drug: Perampanel;   Other: Placebo
Sponsor:   National Institute of Mental Health (NIMH)
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 4, 2019Comments OffAction | AMPA | Antidepressant | Depression | Effects | Ketamine | Major | Mechanism | Patients | Theory | Throughput | TreatmentResistant | Underlying
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

Condition:   Arthritis, Rheumatoid
Interventions:   Biological: GSK3196165;   Drug: Tofacitinib;   Drug: Placebo to GSK3196165;   Drug: Placebo to Tofacitinib;   Drug: csDMARDs
Sponsors:   GlaxoSmithKline;   IQVIA
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 3, 2019Comments OffActive | Antirheumatic | Arthritis | Conventional | cs/Biologic | Disease | DMARDs | Drugs | Efficacy | GSK3196165 | Inadequate | Moderately | Modifying | Participants | Placebo | Response | Rheumatoid | Safety | Severely | Synthetic | Tofacitinib | Versus
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Conditions:   Chronic Lymphocytic Leukemia;   Loss of Chromosome 17p
Interventions:   Drug: Ibrutinib;   Drug: Venetoclax
Sponsors:   Kerry Rogers;   National Cancer Institute (NCI);   Janssen Research & Development, LLC
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 2, 2019Comments OffAfter | Chronic | Ibrutinib | Leukemia | Lymphocytic | Patients | Resistance | Treating | Venetoclax
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Condition:   Multiple Sclerosis, Relapsing-Remitting
Interventions:   Drug: BIIB017 (peginterferon beta-1a);   Drug: Interferon beta type 1a
Sponsor:   Biogen
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 1, 2019Comments OffBeta1a | BIIB017 | Efficacy | Evaluate | Multiple | Participants | Pediatric | PegInterferon | Relapsingremitting | Safety | Sclerosis | Study | Tolerability | Treatment